Drug intelligence / Profile preview

IMW-2001

Development stage: Preclinical
Lead developer: Immunowake
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

IMW-2001 is a preclinical-stage multi-specific cytokine fusion protein (immunocytokine) being developed by Immunowake for the treatment of solid tumors. Engineered using the company's proprietary TTCyto (TIL-Targeted-Cytokine) platform, IMW-2001 is designed to target IL-2, PD-1, and an undisclosed Target B. This multi-specific approach aims to achieve selective activation of tumor-infiltrating lymphocytes (TILs) within the tumor microenvironment, thereby enhancing anti-tumor efficacy while minimizing systemic toxicities typically associated with cytokine therapies.

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)PDCD1 (Programmed cell death protein 1 receptor)BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on IMW-2001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMW-2001.

Explore the full profile